Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Bissery, MC
   Preclinical evaluation of new taxoids
   CURRENT PHARMACEUTICAL DESIGN
   
   M.C. Bissery, "Preclinical evaluation of new taxoids", CUR PHARM D, 7(13), 2001, pp. 1251-1257
2. Campone, M; Fumoleau, P; Delecroix, V; Deporte-Fety, R; Perrocheau, G; Vernillet, L; Borg-Olivier, O; Louboutin, JP; Bissery, MC; Riva, A; Azli, N
   Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
   ANNALS OF ONCOLOGY
   
   M. Campone et al., "Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer", ANN ONCOL, 12(7), 2001, pp. 909-918
3. Granda, TG; Filipski, E; D'Attino, RM; Vrignaud, P; Anjo, A; Bissery, MC; Levi, F
   Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination
   CANCER RESEARCH
   
   T.G. Granda et al., "Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination", CANCER RES, 61(5), 2001, pp. 1996-2001
4. Mailliet, P; Laoui, A; Bourzat, JD; Capet, M; Cheve, M; Commercon, A; Dereu, N; LeBrun, A; Martin, JP; Peyronel, JF; Salagnad, C; Thompson, F; Zucco, M; Guitton, JD; Pantel, G; Bissery, MC; Brealey, C; Lavayre, J; Lelievre, Y; Riou, JF; Vrignaud, P; Duchesne, M; Lavelle, F
   From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase
   FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY
   
   P. Mailliet et al., "From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase", CANC DRUG, 8, 2001, pp. 115-144
5. Veitia, R; David, S; Barbier, P; Vantard, M; Gounon, P; Bissery, MC; Fellous, A
   Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel
   BRITISH JOURNAL OF CANCER
   
   R. Veitia et al., "Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel", BR J CANC, 83(4), 2000, pp. 544-549
6. Veitia, RA; Ottolenghi, C; Bissery, MC; Fellous, A
   A novel human gene, encoding a potential membrane protein conserved from yeast to man, is strongly expressed in testis and cancer cell lines
   CYTOGENETICS AND CELL GENETICS
   
   R.A. Veitia et al., "A novel human gene, encoding a potential membrane protein conserved from yeast to man, is strongly expressed in testis and cancer cell lines", CYTOG C GEN, 85(3-4), 1999, pp. 217-220
7. TAMPELLINI M; FILIPSKI E; LIU XH; LEMAIGRE G; LI XM; VRIGNAUD P; FRANCOIS E; BISSERY MC; LEVI F
   DOCETAXEL CHRONOPHARMACOLOGY IN MICE
   Cancer research
   
   M. Tampellini et al., "DOCETAXEL CHRONOPHARMACOLOGY IN MICE", Cancer research, 58(17), 1998, pp. 3896-3904
8. VELTIA R; BISSERY MC; MARTINEZ C; FELLOUS A
   TAU EXPRESSION IN MODEL ADENOCARCINOMAS CORRELATES WITH DOCETAXEL SENSITIVITY IN TUMOR-BEARING MICE
   British Journal of Cancer
   
   R. Veltia et al., "TAU EXPRESSION IN MODEL ADENOCARCINOMAS CORRELATES WITH DOCETAXEL SENSITIVITY IN TUMOR-BEARING MICE", British Journal of Cancer, 78(7), 1998, pp. 871-877
9. BISSERY MC; VRIGNAUD P; LAVELLE F
   IN-VIVO EVALUATION OF THE IRINOTECAN-OXALIPLATIN COMBINATION
   European journal of cancer
   
   M.C. Bissery et al., "IN-VIVO EVALUATION OF THE IRINOTECAN-OXALIPLATIN COMBINATION", European journal of cancer, 33, 1997, pp. 793-793
10. VASSAL G; BOLAND I; SANTOS A; BISSERY MC; TERRIERLACOMBE MJ; MORIZET J; SAINTEROSE C; LELLOUCHTUBIANA A; KALIFA C; GOUYETTE A
    POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE
    International journal of cancer
    
    G. Vassal et al., "POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE", International journal of cancer, 73(1), 1997, pp. 156-163
11. BISSERY MC; VRIGNAUD P; LAVELLE F; CHABOT GG
    EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE
    Anti-cancer drugs
    
    M.C. Bissery et al., "EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE", Anti-cancer drugs, 7(4), 1996, pp. 437-460
12. ABIGERGES D; ARMAND JP; CHABOT GG; BRUNO R; BISSERY MC; BAYSSAS M; KLINKALAKL M; CLAVEL M; CATIMEL G
    PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS
    Anti-cancer drugs
    
    D. Abigerges et al., "PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS", Anti-cancer drugs, 7(2), 1996, pp. 166-174
13. FROMES Y; GOUNON P; VEITIA R; BISSERY MC; FELLOUS A
    INFLUENCE OF MICROTUBULE-ASSOCIATED PROTEINS ON THE DIFFERENTIAL-EFFECTS OF PACLITAXEL AND DOCETAXEL
    Journal of protein chemistry
    
    Y. Fromes et al., "INFLUENCE OF MICROTUBULE-ASSOCIATED PROTEINS ON THE DIFFERENTIAL-EFFECTS OF PACLITAXEL AND DOCETAXEL", Journal of protein chemistry, 15(4), 1996, pp. 377-388
14. LORUSSO PM; DEMCHIK L; FOSTER B; KNIGHT J; BISSERY MC; POLIN LM; LEOPOLD WR; CORBETT TH
    PRECLINICAL ANTITUMOR-ACTIVITY OF CI-994
    Investigational new drugs
    
    P.M. Lorusso et al., "PRECLINICAL ANTITUMOR-ACTIVITY OF CI-994", Investigational new drugs, 14(4), 1996, pp. 349-356
15. LAVELLE F; BISSERY MC; ANDRE S; ROQUET F; RIOU JF
    PRECLINICAL EVALUATION OF CPT-11 AND ITS ACTIVE METABOLITE SN-38
    Seminars in oncology
    
    F. Lavelle et al., "PRECLINICAL EVALUATION OF CPT-11 AND ITS ACTIVE METABOLITE SN-38", Seminars in oncology, 23(1), 1996, pp. 11-20
16. OJIMA I; SLATER JC; MICHAUD E; KUDUK SD; BOUNAUD PY; VRIGNAUD P; BISSERY MC; VEITH JM; PERA P; BERNACKI RJ
    SYNTHESES AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE 2ND-GENERATION ANTITUMOR TAXOIDS - EXCEPTIONAL ACTIVITY AGAINST DRUG-RESISTANT CANCER-CELLS
    Journal of medicinal chemistry
    
    I. Ojima et al., "SYNTHESES AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE 2ND-GENERATION ANTITUMOR TAXOIDS - EXCEPTIONAL ACTIVITY AGAINST DRUG-RESISTANT CANCER-CELLS", Journal of medicinal chemistry, 39(20), 1996, pp. 3889-3896
17. VASSAL G; TERRIERLACOMBE MJ; BISSERY MC; VENUAT AM; GYERGYAY F; BENARD J; MORIZET J; BOLAND I; ARDOUIN P; BRESSACDEPAILLERETS B; GOUYETTE A
    THERAPEUTIC ACTIVITY OF CPT-11, A DNA-TOPOISOMERASE-I INHIBITOR, AGAINST PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR AND NEUROBLASTOMA XENOGRAFTS
    British Journal of Cancer
    
    G. Vassal et al., "THERAPEUTIC ACTIVITY OF CPT-11, A DNA-TOPOISOMERASE-I INHIBITOR, AGAINST PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR AND NEUROBLASTOMA XENOGRAFTS", British Journal of Cancer, 74(4), 1996, pp. 537-545
18. BISSERY MC
    PRECLINICAL PHARMACOLOGY OF DOCETAXEL
    European journal of cancer
    
    M.C. Bissery, "PRECLINICAL PHARMACOLOGY OF DOCETAXEL", European journal of cancer, 31A, 1995, pp. 1-6
19. BISSERY MC; NOHYNEK G; SANDERINK GJ; LAVELLE F
    DOCETAXEL (TAXOTERE(R)) - A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .1. PRECLINICAL EXPERIENCE
    Anti-cancer drugs
    
    M.C. Bissery et al., "DOCETAXEL (TAXOTERE(R)) - A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .1. PRECLINICAL EXPERIENCE", Anti-cancer drugs, 6(3), 1995, pp. 339-355
20. NGUYEN CH; FAN E; RIOU JF; BISSERY MC; VRIGNAUD P; LAVELLE F; BISAGNI E
    SYNTHESIS AND BIOLOGICAL EVALUATION OF AMINO-SUBSTITUTED BENZO[F]PYRIDO[4,3-B] AND PYRIDO[3,4-B]QUINOXALINES - A NEW CLASS OF ANTINEOPLASTIC AGENTS
    Anti-cancer drug design
    
    C.H. Nguyen et al., "SYNTHESIS AND BIOLOGICAL EVALUATION OF AMINO-SUBSTITUTED BENZO[F]PYRIDO[4,3-B] AND PYRIDO[3,4-B]QUINOXALINES - A NEW CLASS OF ANTINEOPLASTIC AGENTS", Anti-cancer drug design, 10(4), 1995, pp. 277-297
21. MAILLIET P; SEGALBENDIRDJIAN E; KOZELKA J; BARREAU M; BAUDOIN B; BISSERY MC; GONTIER S; LAOUI A; LAVELLE F; LEPECQ JB; CHOTTARD JC
    ASYMMETRICALLY SUBSTITUTED ETHYLENEDIAMINE PLATINUM(II) COMPLEXES AS ANTITUMOR AGENTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS
    Anti-cancer drug design
    
    P. Mailliet et al., "ASYMMETRICALLY SUBSTITUTED ETHYLENEDIAMINE PLATINUM(II) COMPLEXES AS ANTITUMOR AGENTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS", Anti-cancer drug design, 10(1), 1995, pp. 51-73
22. DYKES DJ; BISSERY MC; HARRISON SD; WAUD WR
    RESPONSE OF HUMAN TUMOR XENOGRAFTS IN ATHYMIC NUDE-MICE TO DOCETAXEL (RP-56976, TAXOTERE(R))
    Investigational new drugs
    
    D.J. Dykes et al., "RESPONSE OF HUMAN TUMOR XENOGRAFTS IN ATHYMIC NUDE-MICE TO DOCETAXEL (RP-56976, TAXOTERE(R))", Investigational new drugs, 13(1), 1995, pp. 1-11
23. BISSERY MC; VRIGNAUD P; LAVELLE F
    PRECLINICAL PROFILE OF DOCETAXEL (TAXOTERE) - EFFICACY AS A SINGLE-AGENT AND IN COMBINATION
    Seminars in oncology
    
    M.C. Bissery et al., "PRECLINICAL PROFILE OF DOCETAXEL (TAXOTERE) - EFFICACY AS A SINGLE-AGENT AND IN COMBINATION", Seminars in oncology, 22(6), 1995, pp. 3-16
24. LAVELLE F; BISSERY MC; COMBEAU C; RIOU JF; VRIGNAUD P; ANDRE S
    PRECLINICAL EVALUATION OF DOCETAXEL (TAXOTERE)
    Seminars in oncology
    
    F. Lavelle et al., "PRECLINICAL EVALUATION OF DOCETAXEL (TAXOTERE)", Seminars in oncology, 22(2), 1995, pp. 3-16
25. MASSAAD L; CHABOT GG; TOUSSAINT C; KOSCIELNY S; MORIZET J; BISSERY MC; GOUYETTE A
    INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38
    Cancer chemotherapy and pharmacology
    
    L. Massaad et al., "INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38", Cancer chemotherapy and pharmacology, 34(6), 1994, pp. 497-502
26. RIBRAG V; MASSAAD L; JANOT F; BISSERY MC; PARISE O; GOUYETTE A; CHABOT GG
    PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO
    Leukemia research
    
    V. Ribrag et al., "PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO", Leukemia research, 18(11), 1994, pp. 829-835
27. OJIMA I; DUCLOS O; ZUCCO M; BISSERY MC; COMBEAU C; VRIGNAUD P; RIOU JF; LAVELLE F
    SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEW ANTITUMOR TAXOIDS - EFFECTS OF CYCLOHEXYL SUBSTITUTION AT THE C-3' AND OR C-2 OF TAXOTERE (DOCETAXEL)/
    Journal of medicinal chemistry
    
    I. Ojima et al., "SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEW ANTITUMOR TAXOIDS - EFFECTS OF CYCLOHEXYL SUBSTITUTION AT THE C-3' AND OR C-2 OF TAXOTERE (DOCETAXEL)/", Journal of medicinal chemistry, 37(16), 1994, pp. 2602-2608
28. ECKARDT JR; BURRIS HA; KUHN JG; BISSERY MC; KLINKALAKL M; CLARK GM; VONHOFF DD
    ACTIVITY OF INTOPLICINE (RP60475), A NEW DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO
    Journal of the National Cancer Institute
    
    J.R. Eckardt et al., "ACTIVITY OF INTOPLICINE (RP60475), A NEW DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO", Journal of the National Cancer Institute, 86(1), 1994, pp. 30-33
29. MAURER HR; ECKERT K; BISSERY MC
    TAXOTERE(R) INHIBITS THE PROLIFERATION AND INDUCES THE DIFFERENTIATION OF HL-60 AND K562 HUMAN MYELOID-LEUKEMIA CELLS IN-VITRO
    International journal of oncology
    
    H.R. Maurer et al., "TAXOTERE(R) INHIBITS THE PROLIFERATION AND INDUCES THE DIFFERENTIATION OF HL-60 AND K562 HUMAN MYELOID-LEUKEMIA CELLS IN-VITRO", International journal of oncology, 3(2), 1993, pp. 161-165
30. VOGEL M; HILSENBECK SG; DEPENBROCK H; DANHAUSERRIEDL S; BLOCK T; NEKARDA H; FELLBAUM C; AAPRO MS; BISSERY MC; RASTETTER J; HANAUSKE AR
    PRECLINICAL ACTIVITY OF TAXOTERE (RP-56976, NSC-628503) AGAINST FRESHLY EXPLANTED CLONOGENIC HUMAN TUMOR-CELLS - COMPARISON WITH TAXOL AND CONVENTIONAL ANTINEOPLASTIC AGENTS
    European journal of cancer
    
    M. Vogel et al., "PRECLINICAL ACTIVITY OF TAXOTERE (RP-56976, NSC-628503) AGAINST FRESHLY EXPLANTED CLONOGENIC HUMAN TUMOR-CELLS - COMPARISON WITH TAXOL AND CONVENTIONAL ANTINEOPLASTIC AGENTS", European journal of cancer, 29A(14), 1993, pp. 2009-2014
31. BOVEN E; VENEMAGABERSCEK E; ERKELENS CAM; BISSERY MC; PINEDO HM
    ANTITUMOR-ACTIVITY OF TAXOTERE (RP-56976, NSC-628503), A NEW TAXOL ANALOG, IN EXPERIMENTAL OVARIAN-CANCER
    Annals of oncology
    
    E. Boven et al., "ANTITUMOR-ACTIVITY OF TAXOTERE (RP-56976, NSC-628503), A NEW TAXOL ANALOG, IN EXPERIMENTAL OVARIAN-CANCER", Annals of oncology, 4(4), 1993, pp. 321-324
32. BISSERY MC; NGUYEN CH; BISAGNI E; VRIGNAUD P; LAVELLE F
    ANTITUMOR-ACTIVITY OF INTOPLICINE (RP-60475, NSC-645008), A NEW BENZOPYRIDO-INDOLE - EVALUATION AGAINST SOLID TUMORS AND LEUKEMIAS IN MICE
    Investigational new drugs
    
    M.C. Bissery et al., "ANTITUMOR-ACTIVITY OF INTOPLICINE (RP-60475, NSC-645008), A NEW BENZOPYRIDO-INDOLE - EVALUATION AGAINST SOLID TUMORS AND LEUKEMIAS IN MICE", Investigational new drugs, 11(4), 1993, pp. 263-277
33. RIOU JF; FOSSE P; NGUYEN CH; LARSEN AK; BISSERY MC; GRONDARD L; SAUCIER JM; BISAGNI E; LAVELLE F
    INTOPLICINE (RP-60475) AND ITS DERIVATIVES, A NEW CLASS OF ANTITUMOR AGENTS INHIBITING BOTH TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITIES
    Cancer research
    
    J.F. Riou et al., "INTOPLICINE (RP-60475) AND ITS DERIVATIVES, A NEW CLASS OF ANTITUMOR AGENTS INHIBITING BOTH TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITIES", Cancer research, 53(24), 1993, pp. 5987-5993
34. HOUGHTON PJ; CHESHIRE PJ; HALLMAN JC; BISSERY MC; MATHIEUBOUE A; HOUGHTON JA
    THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST HUMAN TUMOR XENOGRAFTS - LACK OF CROSS-RESISTANCE INVIVO IN TUMORS WITH ACQUIRED-RESISTANCE TO THE TOPOISOMERASE-I INHIBITOR 9-DIMETHYLAMINOMETHYL-10-HYDROXYCAMPTOTHECIN
    Cancer research
    
    P.J. Houghton et al., "THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST HUMAN TUMOR XENOGRAFTS - LACK OF CROSS-RESISTANCE INVIVO IN TUMORS WITH ACQUIRED-RESISTANCE TO THE TOPOISOMERASE-I INHIBITOR 9-DIMETHYLAMINOMETHYL-10-HYDROXYCAMPTOTHECIN", Cancer research, 53(12), 1993, pp. 2823-2829